Clinical Trials Support Core The Clinical Trials Support Core (CTSC) is a shared resource available to all members of the HCCC. It is designed to facilitate execution of high quality clinical cancer investigation including both interventional and correlative science studies. The CTSC enhances interaction among HCCC members and provides for easy assembly of multi-departmental teams needed for collaboration on innovative protocols. The CTSC is composed of dedicated staff with expertise in protocol management and study coordination. Administratively, the Director of the CTSC works closely with the Assistant Director for Clinical Services, and reports to the Associate Director for Clinical and Translational Research. The CTSC provides investigators with appropriate routing of protocols through the various internal regulatory committees including the HCCC Protocol Review and Monitoring Committee, assists the investigator in protocol modifications and reporting of adverse events for ongoing clinical studies, and supplies staff with expertise in data management. The CTSC also provides support for translational research by assisting in the procurement of blood and other not surgical tissues for investigators. It participates in posting protocol lists and supporting internal communication regarding ongoing studies, as well as statistical reporting on accrual. A chargeback system is used to compensate the CTSC for support of most clinical trials run through the CTSC. The core also supports innovative, early phase clinical trials for which there is no other source of support.

Public Health Relevance

The Clinical Trials Support Core provides a centralized resource for investigators interested in clinical and translational cancer research. It is a vital shared resource if we are to translate basic science advances in cancer to the clinic.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Iowa
Iowa City
United States
Zip Code
Chrisman, Matthew; Nothwehr, Faryle; Janz, Kathleen et al. (2015) Perceived Resources and Environmental Correlates of Domain-Specific Physical Activity in Rural Midwestern Adults. J Phys Act Health 12:962-7
Chrisman, Matthew; Nothwehr, Faryle; Yang, Ginger et al. (2015) Environmental influences on physical activity in rural Midwestern adults: a qualitative approach. Health Promot Pract 16:142-8
Makkouk, Amani; Weiner, George J (2015) Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res 75:10-May
Naderi, Ali (2015) Coagulation factor VII is regulated by androgen receptor in breast cancer. Exp Cell Res 331:239-50
McDowell, Bradley D; Chapman, Cole G; Smith, Brian J et al. (2015) Pancreatectomy predicts improved survival for pancreatic adenocarcinoma: results of an instrumental variable analysis. Ann Surg 261:740-5
Ponto, Laura L Boles; Menda, Yusuf; Magnotta, Vincent A et al. (2015) Frontal hypometabolism in elderly breast cancer survivors determined by [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET): a pilot study. Int J Geriatr Psychiatry 30:587-94
Chrischilles, Elizabeth A; McDowell, Bradley D; Rubenstein, Linda et al. (2015) Survivorship care planning and its influence on long-term patient-reported outcomes among colorectal and lung cancer survivors: the CanCORS disease-free survivor follow-up study. J Cancer Surviv 9:269-78
Makkouk, Amani; Joshi, Vijaya B; Wongrakpanich, Amaraporn et al. (2015) Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer. AAPS J 17:184-93
Bhama, A R; Charlton, M E; Schmitt, M B et al. (2015) Factors associated with conversion from laparoscopic to open colectomy using the National Surgical Quality Improvement Program (NSQIP) database. Colorectal Dis 17:257-64
Hoover, Andrew C; Milhem, Mohammed M; Anderson, Carryn M et al. (2015) Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial. Head Neck 37:722-6

Showing the most recent 10 out of 187 publications